Att F - Technical Proposal.xlsx
XLSX spreadsheet 45 KB Posted
- Attached to
- 340b Contract PharmacyBid Documents State and local contract opportunity
- Solicitation number
- 26-84426
- Issued by
- Marion County, Indiana
About this file
This is a Technical Proposal Questionnaire for RFP 26-84426, a 340B Contract Pharmacy solicitation issued by the State of Indiana Department of Corrections (IDOC). The RFP seeks a contract pharmacy vendor to provide comprehensive pharmacy services to eligible patients within IDOC's correctional facilities. Vendors must submit responses to a detailed questionnaire covering general vendor information, definitions related to the 340B Drug Pricing Program, technical capabilities, compliance requirements, and operational responsibilities. The questionnaire requires vendors to indicate agreement with specific terms and conditions using a "Fully Agree," "Partial Agree," or "Disagree" response format, with explanations limited to 50 characters for brief responses or 400 characters for detailed explanations provided on a separate worksheet.
Key operational requirements include establishing a tracking system to prevent drug diversion, maintaining separate records for 340B drugs distinct from the pharmacy's general operations, conducting quarterly reconciliation of drugs dispensed versus received, and providing dedicated support personnel available seven days per week. Vendors must maintain liability insurance of at least $5,000,000 per occurrence and agree to IDOC's audit rights, which extend up to 24 months after contract termination and may occur multiple times annually. The pharmacy must provide patient counseling, drug utilization reviews, medication therapy management, formulary management, and dispense at least a 28-day supply of medications for eligible patients upon release. Vendors must comply with all federal and state laws, HRSA guidance, anti-kickback statutes, and privacy regulations under HIPAA, including safeguards for protected health information and documentation of all PHI disclosures.
View the file
Other files for this state and local contract opportunity
| File | Type | Posted |
|---|---|---|
| RFP 26-84426 - Addendum 1.docx | DOCX document | |
| RFP 26-84426 Main Doc - Addendum 1.pdf | ||
| Att C - Indiana Economic Impact Form.xls | XLS spreadsheet | |
| Att E - Business Proposal.docx | DOCX document | |
| Att D - Cost Proposal.xlsx | XLSX spreadsheet | |
| Att B - Sample Contract.docx | DOCX document | |
| RFP 26-84426 Main Document.pdf | ||
| Att H - Reference Check Form.docx | DOCX document | |
| Att A1 - IVOSB.docx | DOCX document | |
| Exhibit 1 - Facility Locations.docx | DOCX document | |
| Att K - Scope of Work.docx | DOCX document | |
| Att M - Infrastructure Overview.docx | DOCX document | |
| Att J - Attestation Form.docx | DOCX document | |
| Att B3 - IOT-SaaS.docx | DOCX document | |
| Att G - Q&A Template.xlsx | XLSX spreadsheet | |
| Att I - Pre-proposal Network Form.docx | DOCX document | |
| Att L - AI - Technical Questions.docx | DOCX document | |
| Att B2 - IOT-PaaS.docx | DOCX document | |
| Att B1 - IOT-IaaS.docx | DOCX document | |
| Att A - MWBE.docx | DOCX document |
Show all 20
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
1a - Questionnaire
| Attachment F - Techincal Proposal |
| RFP 26-84426 340B Contract Pharmacy for the State of Indiana - Department of Corrections |
| Questionnaire and Minimum Qualifications |
To Vendor: Use Column F to provide a brief explanation. However if the length of the explanation is greater than 50 characters including spaces, you must use the "Explanation" worksheet to provide your detail explanation. Please note, your explanations must be limited to 400 characters or less
| GENERAL VENDOR INFORMATION Corporate Headquarters | Format Type | Response | Explanation | ||
| 1. | 340B Pharmacy Name | Text | |||
| 2. | Street Address | Text | |||
| 3. | City | Text | |||
| 4. | State | Text | |||
| 5. | Zip Code | Text | |||
| 6. | Web Address | Text | |||
| Contacts | Format Type | Response | Explanation | ||
| Please indicate the primary and secondary contact who will answer questions related to this RFP. | |||||
| 7. | Primary Contact | ||||
| a. | Name | Text | |||
| b. | Title | Text | |||
| c. | Address | Text | |||
| d. | City | Text | |||
| e. | State | Text | |||
| f. | Zip | Text | |||
| g. | Phone Number | Text | |||
| h. | Fax Number | Text | |||
| i. | E-mail Address | Text | |||
| 8. | Secondary Contact | ||||
| a. | Name | Text | |||
| b. | Title | Text | |||
| c. | Address | Text | |||
| d. | City | Text | |||
| e. | State | Text | |||
| f. | Zip | Text | |||
| g. | Phone Number | Text | |||
| h. | Fax Number | Text | |||
| i. | E-mail Address | Text |
1b - Definitions
| RFP 26-84426 340B Contract Pharmacy for the State of Indiana - Department of Corrections |
| Definitions |
To Vendor: Use Column F to provide a brief explanation. However if the length of the explanation is greater than 50 characters including spaces, you must use the "Explanation" worksheet to provide your detail explanation. Please note, your explanations must be limited to 400 characters or less
| Definitions | Format Type | Response | Explanation | |
| 1. | "Administrative Fee(s)": means the fee paid to PBM for agreed upon PBM services. | Fully Agree / Partial Agree / Disagree | ||
| 2. | "340B Drugs": covered outpatient drugs, used to treat patients with disease states that are consistent with the Grant(s) that confer Covered Entity status on a facility, purchased at a discounted rate through the 340b Drug Pricing Program in accordance with applicable laws and guidance at 42 U.S.C. 256b(b), 42 U.S.C. 1396r-8(k), and 59 Fed. Reg. 25, 110 (May 13, 1994). | Fully Agree / Partial Agree / Disagree | ||
| 3. | "340b Program": 1992 Veteran’s Health Care Act which created Section 340B of the Public Health Services Act, allowing certain “Covered Entities” to purchase outpatient prescription drugs for their patients at favorable discounts from drug manufacturers who enter drug purchasing agreements with the United States Department of Health and Human Services. | Fully Agree / Partial Agree / Disagree | ||
| 4. | "Covered Entity (CE)": legal entity identified in this proposal including all of its 340B eligible clinic site locations. If there is more than one Covered Entity site which shall be encompassed by this proposal, each site shall be identified in an attachment in this proposal. |
| Eligible Patients: those individuals who satisfy HRSA’s patient definition criteria at 61 Fed. Reg. 55, 156-58 (Oct. 24, 1996), as may be amended from time to time. | Fully Agree / Partial Agree / Disagree | ||
| 5. | “Department": Department of Health and Human Services | Fully Agree / Partial Agree / Disagree | |
| 6. | "Eligible Patients": those individuals who satisfy HRSA's patient definition cirteria at 61 Fed. Reg. 55, 156-158 (Oct. 24, 1996), as may be amended from time to time. | Fully Agree / Partial Agree / Disagree | |
| 7. | “HRSA": Health and Human Resources and Services Administration, which is the agency within the Department that oversees activities of the Office of Pharmacy Affairs. | Fully Agree / Partial Agree / Disagree | |
| 8. | "IDOC": Indiana Department of Correction | Fully Agree / Partial Agree / Disagree | |
| 9. | "IDOH": Indiana Department of Health | Fully Agree / Partial Agree / Disagree | |
| 10. | “Non 340B Price”: Pharmacy’s direct upfront medication cost at the time of dispensing (Actual Acquisition Cost). | Fully Agree / Partial Agree / Disagree | |
| 11. | “OPA": Office of Pharmacy Affairs, which is the federal agency within HRSA that administers the 340B program. | Fully Agree / Partial Agree / Disagree | |
| 12. | “Scope of Work": The work to be performed by the selected pharmacy vendor. | Fully Agree / Partial Agree / Disagree | |
| 13. | “Tracking system": system for identifying and monitoring the use of drugs through all phases of the contact pharmacies involvement with such drugs, including the ordering of 340B drugs, the receipt of 340B drugs, Covered Entity’s payment for 340B drugs, internal transfers of 340B drugs within the Pharmacy, and Pharmacy preparation and dispensing of 340B drugs. | Fully Agree / Partial Agree / Disagree |
1c - Technical Plan Admin
| RFP 26-84426 340B Contract Pharmacy for the State of Indiana - Department of Corrections |
| Technical |
| To Vendor: Use Column F to provide a brief explanation. However if the length of the explanation is greater than 50 characters including spaces, you must use the "Explanation" worksheet to provide your detail explanation. Please note, your explanations must be limited to 400 characters or less | ||||
| Technical Questionnaire | Format Type | Response | Explanation | |
| IDOC Payment Terms | ||||
| 1. | Billing: When pharmacy fills a prescription subject to 340B replenishment under this section, Pharmacy shall bill the CE the compensation dispensing fee. Invoicing shall occur monthly. Payment shall be made by check from CE to Pharmacy by the last day of the following month. Pharmacy will not dispense, bill compensation fee or replenish 340B non-legend medication prescriptions unless both parties agree in writing that pharmacy may do so. Pharmacy shall supply a non-340B price report of all 340B prescriptions dispensed during the invoice period to the CE with each monthly invoice. | Fully Agree / Partial Agree / Disagree | ||
| Essential 340B Requirements | Format Type | Response | Explanation | |
| 2. | Ship to, Bill to Arangement: Covered Entity (CE) shall purchase and maintain title to the 340B Drugs and shall assume all responsibility for establishing the price of the 340B Drugs subject to applicable Federal, State, and local laws. A “ship to, bill to” procedure shall be used by the parties, pursuant to which the CE shall order, or Pharmacy shall order on the CE’s behalf, 340B Drugs directly from the drug manufacturer, a designated sales representative, or a drug wholesaler. The CE, or pharmacy acting on the CE’s behalf, shall arrange for CE to be billed directly for purchased 340B Drugs. CE shall timely pay the party from whom the 340B Drugs were purchased. CE will designate a single billing address for all 340B drug purchases. Shipment of the 340B Drugs will be sent directly to Pharmacy. Pharmacy shall compare all shipments received to the orders and resolve any discrepancy. | Fully Agree / Partial Agree / Disagree | ||
| 3. | Comprehensive Pharmacy Services: The chosen pharmacy agrees to provide comprehensive pharmacy services to Eligible Patients. The respective responsibilities of CE and Pharmacy in providing comprehensive pharmacy service are set forth in Section 4. Certain pharmacy services may be outsourced to a third party, subject to the express written agreement by both the CE and Pharmacy. CE is not limited to providing comprehensive pharmacy services to any location and may choose to provide them at multiple locations. | Fully Agree / Partial Agree / Disagree | ||
| 4. | Adherence to all applicable laws. CE and Pharmacy shall adhere to all applicable Federal, State, and local laws, regulations, and requirements, including but not limited to, HRSA Guidance, Federal, and State anti-kickback laws, self-referral laws, and false claims laws. Both CE and Pharmacy are aware of the potential for civil or criminal penalties if they violate Federal, State, or local laws and requirements. | Fully Agree / Partial Agree / Disagree | ||
| 5. | Reports and Reporting. Pharmacy will provide the CE with reports consistent with customary business practices and HRSA guidelines. The reports that pharmacy shall provide are set forth in a later section. Please provide example reports and explain in the section below how your organization can meet this standard. | Fully Agree / Partial Agree / Disagree | ||
| 6. | Tracking system. Pharmacy, with the assistance of CE, shall establish and maintain a tracking system suitable to prevent the diversion of 340B Drugs to individuals who are not Eligible Patients. The tracking system shall include periodic comparisons of CE prescribing records with pharmacy dispensing records to detect potential irregularities. These comparisons will be completed by the CE. | Fully Agree / Partial Agree / Disagree | ||
| 7. | Patient verification. The parties should develop a system to verify patient eligibility, as defined by HRSA guidance. The system shall be subject to modification in the event of change in such guidelines. The parties agree that they will not resell or transfer a 340B drug to an individual who is not a CE Patient. The CE acknowledges and agrees that it may be removed from the 340B Program if it participates in drug diversion. | Fully Agree / Partial Agree / Disagree | ||
| 8. | Prohibition against duplicate discounts. Neither party shall use 340B Drugs to fill prescriptions for eligible patients payable by Medicaid on a fee-for-service basis or MCO unless CE, Pharmacy, and the State Medicaid program have established an arrangement to prevent duplicate discounts. Any such arrangement shall be reported to HRSA by the CE. | Fully Agree / Partial Agree / Disagree | ||
| 9. | Maintaining compliance. CE and Pharmacy will identify the necessary information for the CE to meet its ongoing obligations of ensuring that the requirements listed are being complied with and establish mechanisms to ensure availability of that information for periodic independent audits performed by the CE. | Fully Agree / Partial Agree / Disagree | ||
| 10. | Outside audits. CE and pharmacy understand that they are subject to audits by outside parties (The Department and participating manufacturers) of records that directly pertain to the CE’s compliance with HRSA guidance. Pharmacy assures that all pertinent reimbursement accounts and dispensing records maintained by the pharmacy will be accessible separately from Pharmacy’s own operations and will be made available to CE, HRSA, and applicable manufacturers in the case of an audit. Such auditable records shall be maintained for a period that complies with all applicable Federal, State, and local requirements. | Fully Agree / Partial Agree / Disagree | ||
| 18. | Access to agreement. Upon written request to the CE, a copy of any agreements will be made available to OPA. | Fully Agree / Partial Agree / Disagree | ||
| 19. | Pharmacy Site(s). Pharmacy shall provide the services contracted for locations listed in Exhibit XX. | Fully Agree / Partial Agree / Disagree | ||
| Ongoing Responsibility of CE and Pharmacy to Ensure Compliance: In addition to the responsibilities described above, CE and vendor agree to operationalize the contract pharmacy agreement by performing the following operation responsibilities. | Format Type | Response | Explanation | |
| 20. | Replenishment: The parties agree to establish and utilize a stock replacement system whereby the ordering and receipt of 340B Drugs occurs upon Pharmacy filing a prescription for a qualified CE Patient. | Fully Agree / Partial Agree / Disagree | ||
| 21. | Ordering: CE shall arrange for Pharmacy to place orders for 340B Drugs on CE’s behalf from the wholesaler. Pharmacy will not order and thus ship provider floor stock from the CE’s 340B wholesaler account to any Facility unless both parties agree in writing that the pharmacy may do so. | Fully Agree / Partial Agree / Disagree | ||
| 22. | Shipment: CE shall arrange for shipment of the 340B Drugs directly to the pharmacy from the wholesaler. Pharmacy shall dispense 340B drugs to IDOC correctional facilities. | Fully Agree / Partial Agree / Disagree | ||
| 23. | Receipt of 340B Drugs. Pharmacy is responsible for the receipt of 340B Drugs purchased by CE. Upon receipt of 340B Drugs, Pharmacy shall compare all shipments received on behalf of CE and confirm that the shipments conform to the orders of 340B Drugs placed by CE. If Pharmacy should find a discrepancy between the shipment and order of 340B covered outpatient drugs, Pharmacy shall inform the CE. | Fully Agree / Partial Agree / Disagree | ||
| 24. | NDC-by-NDC Replacement: Drugs dispensed Eligible Patients shall be replenished at the NDC-11 level. In the event the drug cannot be replenished at the NDC-11 level, the parties agree to follow the procedures outlined in the sections below. | Fully Agree / Partial Agree / Disagree | ||
| 25. | Billing: When pharmacy fills a prescription subject to 340B replenishment under this section, Pharmacy shall bill the CE the compensation dispensing fee. Invoicing shall occur monthly. Payment shall be made by check from CE to Pharmacy by the last day of the following month. Pharmacy will not dispense, bill compensation fee or replenish 340B non-legend medication prescriptions unless both parties agree in writing that pharmacy may do so. Pharmacy shall supply a non-340B price report of all 340B prescriptions dispensed during the invoice period to the CE with each monthly invoice. | Fully Agree / Partial Agree / Disagree | ||
| 26. | Out of Stock, Unavailable, or Discontinued Drugs. When a replenishment order is for a drug that is out of stock, the out of stock will be reordered in the next inventory replenishment order. After two (2) consecutive invoice periods the drug(s) remain out of stock, or it is determined to be completely unavailable the parties agree that the prescription will not be replenished with 340B drugs and the pharmacy will bill the CE the pharmacy’s non-340B price for said prescriptions the following invoice period. In the event the drug is in stock, but its package size has been discontinued, the parties agree that the drug shall be replenished in the next available package size (at the NDC-9 level). | Fully Agree / Partial Agree / Disagree | ||
| 27. | Slow Moving Drugs. Pharmacy will identify all drugs that have been dispensed to Eligible Patients but do not qualify for a 340B replenishment order because the quantity of such drugs falls short of the NDC-11 package size necessary to trigger replenishment with 340B drugs. If more than three (3) months have passed since the non-replenished drugs have been dispensed, the parties agree that pharmacy will determine at its discretion if they will no longer seek to replenish the drugs and will use Pharmacy’s non-340B drugs instead. If Pharmacy determines they will no longer continue to try to seek replenishment, pharmacy will bill the CE the non-340B price for said prescriptions the following invoice period. The pharmacy should make the CE aware prior to dispensing drugs at the non-340B price. | Fully Agree / Partial Agree / Disagree | ||
| 28. | Reconciliation. Pharmacy will conduct a quarterly reconciliation of 340B Drugs dispensed against those 340B Drugs received. The pharmacy shall have a system in place to resolve any discrepancies as a result of the dispensed drugs being out of stock, discontinued, or slow moving. Pharmacy will return any excess supply of 340B Drugs to the wholesaler. | Fully Agree / Partial Agree / Disagree | ||
| 29. | Unused Drugs. In the event a drug dispensed by pharmacy is unused, since pharmacy is using the replenishment method, the drug cannot be returned to pharmacy for re-dispensing. However, if the pharmacy has orders that are unfilled and undispensed those may be returned to the manufacturer for credit to the CE. The CE will use an identified and licensed reverse distributor when applicable. | Fully Agree / Partial Agree / Disagree | ||
| 30. | Patient verification. CE shall furnish a list to pharmacy of all health care providers qualified to prescribe 340B Drugs to eligible patients. The CE authorizes the pharmacy to use 340B Drugs to fill any prescription from an individual identified in the list. The list shall be updated at a minimum of each quarter with any immediate additions or deletions communicated to pharmacy as they occur. Pharmacy will not dispense any 340B medications to non-incarcerated eligible patients. | Fully Agree / Partial Agree / Disagree | ||
| 31. | Tracking system. Pharmacy shall establish a tracking system to protect against diversion and duplicate discounts throughout the process by which 340B Drugs are ordered, received, dispensed, and billed. | Fully Agree / Partial Agree / Disagree | ||
| 32. | Records. Pharmacy shall maintain readily retrievable customary business records including prescription files, records of ordering and receipt, dispensing records, any third-party reimbursement claims | Fully Agree / Partial Agree / Disagree | ||
| 33. | Inspection. The CE shall have the opportunity, upon reasonable notice and during business hours, to examine the Tracking system. | Fully Agree / Partial Agree / Disagree | ||
| 34. | Modification. The pharmacy shall make all adjustments to the tracking system that the CE determines are reasonably necessary to prevent the diversion of 340B Drugs to individuals who are not eligible patients. | Fully Agree / Partial Agree / Disagree | ||
| 35. | 340B Third Party Management Software. The pharmacy shall have and maintain its own third party 340B inventory management system. | Fully Agree / Partial Agree / Disagree | ||
| 36. | Record Keeping. The pharmacy agrees to maintain auditable records relating to the purchase, dispensing, and billing of 340B Drugs. Pharmacy will produce records relating to the purchase, dispensing, and billing of 340B upon request of the CE. Monthly records will be forwarded to the CE. | Fully Agree / Partial Agree / Disagree | ||
| 37. | Maintenance of Pharmacy Services Record. Pharmacy shall maintain all relevant records in accordance with applicable Federal, State, and local laws and regulations, including but not limited to the Federal standards for the privacy of individually identifiable health information and the HRSA Guidance. Pharmacy shall maintain all auditable records for a period of time that complies with all applicable Federal, State, and local requirements, and in any event not less than a period of ten (10) years. | Fully Agree / Partial Agree / Disagree | ||
| 38. | Access to business records. Pharmacy shall provide the CE with reasonable access to pharmacy’s business records relating to pharmacy services for 340B Drugs, as is deemed necessary by CE to ensure that pharmacy follows applicable Federal, State, and local laws, regulations, and requirements, and HRSA Guidance. | Fully Agree / Partial Agree / Disagree | ||
| 39. | Separation of Records. Pharmacy shall ensure that all reimbursement accounts and dispensing records, and all other pertinent records relating to pharmacy’s responsibilities and duties are maintained by pharmacy separately from the pharmacy’s own operations. | Fully Agree / Partial Agree / Disagree | ||
| 40. | Other Pharmacy Responsibilities: | Fully Agree / Partial Agree / Disagree | ||
| 41. | Practice of Pharmacy. Pharmacy agrees to render services in accordance with the rules and regulations of the State Board of Pharmacy and all applicable Federal and State laws and regulations. The relations between eligible patients and pharmacy shall be subject to the rules, limitations, and privileges incident to the pharmacy-patient relationship. Pharmacy shall be responsible to said eligible patients for pharmaceutical advice and service, including the right to refuse to service any individual where such service would violate pharmacy ethics or any pharmacy laws or regulations. | Fully Agree / Partial Agree / Disagree | ||
| 42. | Patient Counseling. Pharmacy shall provide patient counseling services to eligible patients in accordance with applicable Federal, State, and local laws and regulations. | Fully Agree / Partial Agree / Disagree | ||
| 43. | Drug Utilization Review. Pharmacy shall perform drug utilization review for eligible patients. | Fully Agree / Partial Agree / Disagree | ||
| 44. | Medication Therapy Management. Pharmacy shall provide consultations and other services to optimize therapeutic outcomes through improved mediation use and decreased adverse drug interactions. | Fully Agree / Partial Agree / Disagree | ||
| 45. | Formulary Management. Pharmacy shall provide formulary management. | Fully Agree / Partial Agree / Disagree | ||
| 46. | Pharmacy will provide a dedicated pharmacist/ person to respond to 340B pharmacy related needs of the CEs via telephone or email during business hours. | Fully Agree / Partial Agree / Disagree | ||
| 47. | The pharmacy will provide a dedicated team member to respond to calls from CE facilities, help troubleshoot issues, fill prescriptions, and ensure medications are received in a timely fashion at a minimum of 7 days per week. | Fully Agree / Partial Agree / Disagree | ||
| 48. | Pharmacy should ensure a refill system is in place with all of the CE’s facilities. | Fully Agree / Partial Agree / Disagree | ||
| 49. | Pharmacy shall provide at least a 28-day supply of covered medications for each eligible patient at the time of release. | Fully Agree / Partial Agree / Disagree | ||
| 50. | Pharmacy shall conduct allergy, interaction, dosage checks, and other professional pharmacy services associated with medication dispensing for all prescriptions filled. | Fully Agree / Partial Agree / Disagree | ||
| 51. | Pharmacy should verify dosage, provide drug information, and other pharmacy related services. The pharmacy shall send fill reports and shipped reports to each facility | Fully Agree / Partial Agree / Disagree | ||
| IDOC Compliance Management Rights - General | Format Type | Response | Explanation | |
| 52. | IDOC retains the right to audit such information as reasonably required to determine that your firm is complying with the Agreement, which includes but is not limited to: 100% of 340B requirements, and IDOC health services policy and procedure. | Fully Agree / Partial Agree / Disagree | ||
| 53. | Each and every payment by IDOC to the vendor would be subject to audit and reconciliation and no such payment made by IDOC would constitute a waiver of its right to audit or reconcile. | Fully Agree / Partial Agree / Disagree | ||
| 54. | Audits may be performed annually, at any time as determined by IDOC. | Fully Agree / Partial Agree / Disagree | ||
| 55. | IDOC retains the right to perform additional audits of similar scope at no additional charge during the year if requested as a follow-up to ensure significant/material errors found in any prior audit have been corrected and are not recurring, or if additional information becomes available to warrant further investigation. | Fully Agree / Partial Agree / Disagree | ||
| 56. | IDOC retains the right to audit more than once per year if the audits are different in scope or for different services. | Fully Agree / Partial Agree / Disagree | ||
| 57. | IDOC retains the right to audit up to twenty-four (24) months after the termination of this Agreement. | Fully Agree / Partial Agree / Disagree | ||
| 58. | Vendor agrees to provide reasonable cooperation with requests for information, which includes but is not limited to the timing of the audit, deliverables, data/information requests and your response time to IDOC questions during and after the process. Vendor will also provide a response to all "findings" it receives within 30 calendar days, or at a later date if mutually determined to be more reasonable based on the number and type of findings. To the extent the auditor has follow up questions to your responses, you will acknowledge receipt of the question with 48 hours and provide a formal response with answers to auditors questions within five business days | Fully Agree / Partial Agree / Disagree | ||
| 59. | If the audit identifies dificiencies, vendor will provide corrective action plans to IDOC for each area that is dificient. | Fully Agree / Partial Agree / Disagree | ||
| 60. | Vendor will provide monthly fill reports, active order reports, wholesale order report summaries, and virtual onsite 340B inventory to IDOC. | Fully Agree / Partial Agree / Disagree | ||
| 61. | Vendor will meet with IDOC leadership at least quarterly and partake in the P&T meetings quarterly. | Fully Agree / Partial Agree / Disagree | ||
| 62. | Vendor agrees to provide accomodation and reports for all independent 340B related audits. | |||
| Liability/Regulatory | Format Type | Response | Explanation | |
| 63. | Your firm maintains a fidelity bond. | Fully Agree / Partial Agree / Disagree | ||
| Your firm maintains liability coverage with limits not less than $5,000,000 per occurrence and in the aggregate per policy year, with excess liability coverage in the amount not less than $5,000,000 per policy year. Evidence thereof will be furnished to IDOC upon request. | Fully Agree / Partial Agree / Disagree | |||
| 64. | If not, please explain amount of coverage. | Text | ||
| 65. | Liability insurance covers: medical management decisions | Fully Agree / Partial Agree / Disagree | ||
| 66. | Liability insurance covers: professional malpractice | Fully Agree / Partial Agree / Disagree | ||
| 67. | Liability insurance covers: provider contracting | Fully Agree / Partial Agree / Disagree | ||
| 68. | You agree to indemnify and hold IDOC harmless for your negligence or for your failure to perform under the Agreement. IDOC shall not provide any indemnity in favor of your firm. | Fully Agree / Partial Agree / Disagree | ||
| 69. | Please describe any judgment or settlement during the past three (3) years or pending litigation that could result in judgments or settlements in excess of $100,000. | Fully Agree / Partial Agree / Disagree | ||
| Compliance – Privacy and Confidentiality | Format Type | Response | Explanation | |
| 70. | You will not use or further disclose protected health information (PHI) other than as permitted or as required by law. | Fully Agree / Partial Agree / Disagree | ||
| 71. | You will use appropriate safeguards to prevent the unauthorized use or disclosure of the PHI. You will report to IDOC any unauthorized use or disclosure of the PHI. | Fully Agree / Partial Agree / Disagree | ||
| 72. | You will mitigate, to the extent practicable, any harmful effect that is known to you of a use or disclosure of PHI by your firm in violation of the requirements of the federal privacy rule. | Fully Agree / Partial Agree / Disagree | ||
| 73. | You will provide access to PHI in a "designated record set" in order to meet the requirements under 45 CFR §164.524. | Fully Agree / Partial Agree / Disagree | ||
| 74. | You will make any amendment(s) to PHI in a "designated record set" pursuant to 45 CFR §164.526. | Fully Agree / Partial Agree / Disagree | ||
| 75. | You will document such disclosures of PHI and information related to such disclosures as would be required to respond to a request by an individual for an accounting of disclosures of PHI in accordance with 45 CFR §164.528. | Fully Agree / Partial Agree / Disagree | ||
| 76. | You will (i) implement administrative, physical, and technical safeguards that reasonably and appropriately protect the confidentiality, integrity, and availability of the electronic PHI that your firm creates, receives, maintains, or transmits, (ii) report to IDOC any security incident (within the meaning of 45 CFR §164.304) of which you become aware, and (iii) ensure that any employee of your firm or agent, including any subcontractor to whom you provide PHI received from, or created or received by your firm agrees to implement reasonable and appropriate safeguards to protect such PHI. | Fully Agree / Partial Agree / Disagree | ||
| Systems - General | Format Type | Response | Explanation | |
| 77. | Next Gen access will be provided to gain orders for 340B medications. | Fully Agree / Partial Agree / Disagree |
DropDown
| Included | Yes | Fully Agree | Yes | Complete | Wholly Owned | Confirmed | At least quarterly | Monthly | PM |
| Excluded | No | Partial Agree | No, Explain | Not Complete | Outsourced | Not Confirmed | At least semi-annually | Quarterly | PE |
| Included Channel Agnostic | Disagree | At least annually | Semi-Annually | PEPM | |||||
| Excluded Channel Agnostic | Other, specify | Annually | PMPM | ||||||
| Other, Explain |
Explanation
| RFP 26-84426 340B Contract Pharmacy for the State of Indiana - Department of Corrections |
| Explanation |
| This worksheet should be used to provide additional explanations for any questions for which a "See Explanation" response |
| was given. Explanations must be numbered to correspond to the question to which they pertain and they must be brief. |
State the number of questions you addressed with further explanation:
Sheet Name Question # Explanation
File details come from the government source that posted it. Updated .